{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:04:24Z","timestamp":1791594264569,"version":"4.3.4"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The emergence of fentanyl and other high-potency synthetic opioids (HPSOs) has not only been underlying overdose deaths, but has complicated initiation of methadone and buprenorphine for opioid use disorder (OUD) treatment, including in the hospital. In response, clinicians with addiction expertise have developed novel initiation practices, yet no studies have characterized initiation practices nationally.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the use of novel hospital-based practices for initiating methadone and buprenorphine.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional survey study of directors of hospital-based addiction consult services (ACS) associated with addiction medicine and addiction psychiatry fellowships in hospitals in the US was conducted using a REDcap anonymous survey from October 2023 to April 2024.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Predefined methadone and buprenorphine initiation practices. Standard methadone initiation was defined as 40 mg oral maximum on day 1 with up-titration of 5 to 10 mg every 3 days. Rapid methadone initiation was defined as any initiation regimen more rapid than standard. Buprenorphine initiation practices included low dose, high dose, traditional, and rescue.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was the proportion of ACS directors using predefined methadone and buprenorphine initiation practices. Perceived impact of the drug supply on methadone and buprenorphine initiation was assessed through a 5-point Likert scale ranging from strongly disagree to strongly agree. Typical selection of buprenorphine initiation practices was assessed using 7 case-based scenarios intended to represent common hospital scenarios.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 80 consult services, 58 directors (72.5%; median [IQR] age, 41 [38-50] years; 27 of 57 [47.3%] women) completed surveys, one of which was partially completed. Of 57 ACS directors, specialties included addiction medicine (41 respondents [71.9%]), addiction psychiatry (11 respondents [19.3%]), general or consult liaison psychiatry (11 respondents [19.3%]), and toxicology (2 respondents [3.5%]). Among those who reported initiating methadone (47 of 58 respondents [81.0%]), 33 (70.2%) agreed that HPSOs changed their methadone initiation practices. Of 46 respondents, 40 (87.0%) reported rapid initiation of methadone, and of those, 26 (65.0%) reported using rapid initiation for more than 50% of initiations. Full-agonist opioids were used by 31 of 46 ACS directors (67.4%) to treat withdrawal during methadone initiation. Of 58 respondents, 54 (93.1%) agreed that HPSOs changed their buprenorphine initiation practices. All 58 ACS directors reported that their initiation practices offered buprenorphine initiation, including 53 of 57 (92.9%) offering low dose, 50 of 57 (87.7%) offering traditional, 43 of 57 (75.4%) offering high dose , and 20 of 57 (35.1%) offering rescue. For 7 clinical cases provided, low-dose initiation was the most commonly endorsed method of buprenorphine initiation, except in the case of a person presenting in significant withdrawal 2 days after last fentanyl use.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings of this survey study of hospital-based academic ACS directors suggest that methadone and buprenorphine initiation has adapted to a shifting opioid supply, often outpacing research and changes in clinical guidelines.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.26077","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:31:07Z","timestamp":1754580667000},"page":"e2526077","source":"Crossref","is-referenced-by-count":9,"title":["Hospital-Based Methadone and Buprenorphine Initiation Practices by Addiction Consult Services"],"prefix":"10.1001","volume":"8","author":[{"given":"Shawn M.","family":"Cohen","sequence":"first","affiliation":[{"name":"Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elana","family":"Straus","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fiellin","sequence":"additional","affiliation":[{"name":"Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Pomeranz","sequence":"additional","affiliation":[{"name":"Department of Occupational Therapy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette M.","family":"Tetrault","sequence":"additional","affiliation":[{"name":"Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa B.","family":"Weimer","sequence":"additional","affiliation":[{"name":"Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Jennifer","family":"Edelman","sequence":"additional","affiliation":[{"name":"Program in Addiction Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Social and Behavioral Sciences, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Joudrey","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"},{"name":"Center for Research on Health Care, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"2S","key":"zoi250735r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0000000000000633","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update.","volume":"14","year":"2020","journal-title":"J Addict Med"},{"issue":"4","key":"zoi250735r4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/ADM.0000000000000952","article-title":"A plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the fentanyl era.","volume":"16","author":"Sue","year":"2022","journal-title":"J Addict Med"},{"issue":"6","key":"zoi250735r5","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.1097\/ADM.0000000000001007","article-title":"Buprenorphine initiation in the era of high-potency synthetic opioids: a call for community-based participatory research to help learning health systems provide precision medicine for opioid use disorder.","volume":"16","author":"Fiellin","year":"2022","journal-title":"J Addict Med"},{"issue":"3","key":"zoi250735r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.6108","article-title":"Incidence of precipitated withdrawal during a multisite emergency department-initiated buprenorphine clinical trial in the era of fentanyl.","volume":"6","author":"D\u2019Onofrio","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi250735r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.35895","article-title":"Buprenorphine-precipitated withdrawal among hospitalized patients using fentanyl.","volume":"7","author":"Thakrar","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi250735r8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.12.005","article-title":"Fentanyl: receptor pharmacology, abuse potential, and implications for treatment.","volume":"106","author":"Comer","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"zoi250735r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108832","article-title":"Adapting methadone inductions to the fentanyl era.","volume":"141","author":"Buresh","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"zoi250735r10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/add.14522","article-title":"What should clinicians do as fentanyl replaces heroin?","volume":"114","author":"Bisaga","year":"2019","journal-title":"Addiction"},{"key":"zoi250735r11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"\u201cEverything is not right anymore\u201d: buprenorphine experiences in an era of illicit fentanyl.","volume":"74","author":"Silverstein","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"4","key":"zoi250735r12","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1097\/ADM.0000000000000922","article-title":"Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl.","volume":"16","author":"Varshneya","year":"2021","journal-title":"J Addict Med"},{"issue":"4","key":"zoi250735r13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.mcna.2018.03.001","article-title":"Inpatient addiction consult service: expertise for hospitalized patients with complex addiction problems.","volume":"102","author":"Weinstein","year":"2018","journal-title":"Med Clin North Am"},{"issue":"10","key":"zoi250735r14","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s11606-021-07362-8","article-title":"Inpatient addiction medicine consultation service impact on post-discharge patient mortality: a propensity-matched analysis.","volume":"37","author":"Wilson","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"6","key":"zoi250735r15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/ADM.0000000000001207","article-title":"Safety and efficacy of rapid methadone titration for opioid use disorder in an inpatient setting: a retrospective cohort study.","volume":"17","author":"Klaire","year":"2023","journal-title":"J Addict Med"},{"key":"zoi250735r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209004","article-title":"Safety of rapid inpatient methadone initiation protocol: a retrospective cohort study.","volume":"148","author":"Racha","year":"2023","journal-title":"J Subst Use Addict Treat"},{"issue":"3","key":"zoi250735r17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/08897077231185655","article-title":"Rapid methadone induction in a general hospital setting: a retrospective, observational analysis.","volume":"44","author":"Casey","year":"2023","journal-title":"Subst Abus"},{"issue":"4","key":"zoi250735r18","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/ADM.0000000000001324","article-title":"Piloting a hospital-based rapid methadone initiation protocol for fentanyl.","volume":"18","author":"Liu","year":"2024","journal-title":"J Addict Med"},{"issue":"6","key":"zoi250735r19","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","article-title":"ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids.","volume":"17","author":"Weimer","year":"2023","journal-title":"J Addict Med"},{"issue":"4","key":"zoi250735r20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/ADM.0000000000001296","article-title":"High-dose buprenorphine initiation: a scoping review.","volume":"18","author":"Wong","year":"2024","journal-title":"J Addict Med"},{"issue":"4","key":"zoi250735r21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/ADM.0000000000000945","article-title":"Low dose initiation of buprenorphine: a narrative review and practical approach.","volume":"16","author":"Cohen","year":"2022","journal-title":"J Addict Med"},{"issue":"5","key":"zoi250735r25","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/ADM.0000000000001163","article-title":"Survey of buprenorphine low-dose regimens used by healthcare institutions.","volume":"17","author":"Hardy","year":"2023","journal-title":"J Addict Med"},{"issue":"2","key":"zoi250735r26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/poq\/nfm006","article-title":"Research synthesis: the practice of cognitive interviewing.","volume":"71","author":"Beatty","year":"2007","journal-title":"Public Opin Q"},{"issue":"4","key":"zoi250735r27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/ADM.0000000000000935","article-title":"Rapid transition to buprenorphine in a patient with methadone-related QTc interval prolongation.","volume":"16","author":"Brogdon","year":"2022","journal-title":"J Addict Med"},{"issue":"2","key":"zoi250735r28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/ADM.0000000000001073","article-title":"Enhancing patient choice: using self-administered intranasal naloxone for novel rapid buprenorphine initiation.","volume":"17","author":"Randall","year":"2023","journal-title":"J Addict Med"},{"issue":"2","key":"zoi250735r29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"zoi250735r30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners.","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"23","key":"zoi250735r32","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1001\/jama.2023.21288","article-title":"Trends in before medically advised discharges for patients with opioid use disorder, 2016-2020.","volume":"330","author":"Thakrar","year":"2023","journal-title":"JAMA"},{"key":"zoi250735r33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.socscimed.2014.01.010","article-title":"Hospitals as a \u2018risk environment\u2019: an ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs.","volume":"105","author":"McNeil","year":"2014","journal-title":"Soc Sci Med"},{"issue":"1","key":"zoi250735r34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13722-023-00368-z","article-title":"Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.","volume":"18","author":"Thakrar","year":"2023","journal-title":"Addict Sci Clin Pract"},{"issue":"3","key":"zoi250735r35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.1572","article-title":"High-dose buprenorphine initiation in the emergency department among patients using fentanyl and other opioids.","volume":"6","author":"Snyder","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi250735r36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/add.16646","article-title":"Incidence of buprenorphine-precipitated opioid withdrawal in adults with opioid use disorder: a systematic review.","volume":"120","author":"Gregory","year":"2025","journal-title":"Addiction"},{"issue":"2","key":"zoi250735r37","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1097\/ADM.0000000000000864","article-title":"Low-dose buprenorphine initiation in hospitalized adults with opioid use disorder: a retrospective cohort analysis.","volume":"16","author":"Button","year":"2022","journal-title":"J Addict Med"},{"issue":"1","key":"zoi250735r38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/ADM.0000000000001236","article-title":"Evaluation of low-dose buprenorphine initiation with buprenorphine buccal films in hospitalized patients: a retrospective cohort study.","volume":"18","author":"Arnouk","year":"2024","journal-title":"J Addict Med"},{"issue":"4","key":"zoi250735r39","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/ADM.0000000000001146","article-title":"Low-dose initiation of buprenorphine in hospitalized patients using buccal buprenorphine: a case series.","volume":"17","author":"Adams","year":"2023","journal-title":"J Addict Med"},{"issue":"4","key":"zoi250735r40","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1097\/ADM.0000000000001133","article-title":"Rapid low-dose buprenorphine initiation for hospitalized patients with opioid use disorder.","volume":"17","author":"Sokolski","year":"2023","journal-title":"J Addict Med"},{"key":"zoi250735r41","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108314","article-title":"Steep increases in fentanyl-related mortality west of the Mississippi River: recent evidence from county and state surveillance.","volume":"216","author":"Shover","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi250735r42","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109380","article-title":"Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis.","volume":"233","author":"Friedman","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"zoi250735r43","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","article-title":"The answer is 17 years, what is the question: understanding time lags in translational research.","volume":"104","author":"Morris","year":"2011","journal-title":"J R Soc Med"},{"issue":"29","key":"zoi250735r45","doi-asserted-by":"publisher","first-page":"940","DOI":"10.15585\/mmwr.mm7129e2","article-title":"Vital signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics\u201425 states and the District of Columbia, 2019-2020.","volume":"71","author":"Kariisa","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"zoi250735r46","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1176\/appi.ajp.20230917","article-title":"Understanding and addressing widening racial inequalities in drug overdose.","volume":"181","author":"Friedman","year":"2024","journal-title":"Am J Psychiatry"},{"key":"zoi250735r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109859","article-title":"US drug overdose mortality rose faster among Hispanics than non-Hispanics from 2010 to 2021.","volume":"246","author":"Romero","year":"2023","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi250735r48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/29767342231210210","article-title":"Recruiting and retaining a diverse and skilled addiction treatment workforce.","volume":"45","author":"Paradise","year":"2024","journal-title":"Subst Use Addctn J"},{"key":"zoi250735r31"},{"key":"zoi250735r1","doi-asserted-by":"crossref","unstructured":"Leshner? AI, Mancher? M, eds. Medications for opioid use disorder save lives. National Academies of Sciences, Engineering, and Medicine. Published 2019. Accessed July 2, 2025. https:\/\/nap.nationalacademies.org\/catalog\/25310\/medications-for-opioid-use-disorder-save-lives","DOI":"10.17226\/25310"},{"key":"zoi250735r2","unstructured":"Substance Abuse and Mental Health Services Administration. Tip 63: medications for opioid use disorder. Published July 2021. Accessed July 2, 2025. https:\/\/library.samhsa.gov\/product\/tip-63-medications-opioid-use-disorder\/pep21-02-01-002"},{"key":"zoi250735r22","unstructured":"American Association of Public Opinion Research. AAPOR transparency initiative disclosure elements. Updated April 2021. Accessed May 19, 2025. https:\/\/aapor.org\/wp-content\/uploads\/2022\/11\/TI-Attachment-C.pdf"},{"key":"zoi250735r23","unstructured":"Accredidation Council for Graduate Medical Education. Addiction psychiatry programs academic year 2020-2021. American Academy of Addiction Psychiatry. Published September 9, 2020. Accessed November 8, 2023. https:\/\/www.aaap.org\/wp-content\/uploads\/2020\/09\/ACGME_Addiction_Psychiatry_2020-2021.pdf"},{"key":"zoi250735r24","unstructured":"American College of Academic Addiction Medicine. ACAAM addiction medicine fellowship directory. Published 2023. Accessed November 8, 2023. https:\/\/web.archive.org\/web\/20230322153322\/https:\/\/www.acaam.org\/assets\/docs\/Fellowship\/FELLOWSHIP%20DIRECTORY%20(2-28-23).pdf"},{"key":"zoi250735r44","unstructured":"Fitch? K, Bernstein? SJ, Aguilar? MD, . RAND\/UCLA appropriateness method user\u2019s manual. RAND Corporation. Published 2001. Accessed July 2, 2025. https:\/\/www.rand.org\/pubs\/monograph_reports\/MR1269.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2837335\/cohen_2025_oi_250735_1753911754.31213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:31:12Z","timestamp":1754580672000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2837335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.26077","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]}}}